Thoracoscopic epicardial pulmonary vein ablation for lone paroxysmal atrial fibrillation

Abstract Surgical treatment of atrial fibrillation recently gained new popularity since the introduction of different energy sources for ablative therapy as an alternative to the original ''cut-and-sew'' techniques. However, most of the cases have been performed together with other cardiac surgical procedures and mainly through a standard median sternotomy approach. We report here the first European case of closed-chest thoracoscopic pulmonary vein isolation in a patient with lone paroxysmal atrial fibrillation

Prolonged donor ischemic time does not adversely affect long-term survival in adult patients undergoing cardiac transplantation

AbstractObjectiveWith liberalization of donor eligibility criteria, organs are being harvested from remote locations, increasing donor ischemic times. Although several studies have evaluated the effects of prolonged donor ischemic times on short-term survival and graft function, few have addressed concerns regarding long-term survival.MethodsOver the last 11 years, 819 consecutive adults underwent cardiac transplantation at Columbia Presbyterian Medical Center. Recipients were separated into the following 4 groups based on donor ischemic time: <150 minutes, 150 to 200 minutes, 200 to 250 minutes, and >250 minutes. Statistical analysis included Kaplan-Meier survival and Cox proportional hazard models to identify predictors of long-term survival.ResultsDonor ischemic time was 120.1 ± 21.1 minutes for group 1 (n = 321), 174.1 ± 14.7 minutes for group 2 (n = 264), 221.7 ± 14.6 minutes for group 3 (n = 154), and 295.5 ± 37.1 minutes for group 4 (n = 80) (P < .001). There were no significant differences in recipient age, donor age, etiology of heart failure, United Network for Organ Sharing status, or history of previous cardiac surgery among the groups (P = NS). Prolonged donor ischemic time did not adversely affect long-term survival, with actuarial survival at 1, 5, and 10 years of 86.9%, 75.2%, and 56.4% for group 1; 86.2%, 76.9%, and 50.9% for group 2; 86.4%, 71.0%, and 43.7% for group 3; and 86.7%, 70.1%, and 50.9% for group 4 (P = .867). There was no significant difference in freedom from transplant coronary artery disease among the 4 groups (P = .474).ConclusionsProlonged donor ischemic time is not a risk factor for decreased long-term survival. Procurement of hearts with prolonged donor ischemic time is justified in the setting of an increasing recipient pool with a fixed donor population